Taltz ® (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Taltz Summary of Product Characteristics (SmPC)

Taltz® (ixekizumab): How to confirm dose delivery

The dose was delivered when: in the pre-filled pen - the grey plunger is visible at the top of the clear base; in the pre-filled syringe - the green plunger rod is visible through the syringe body.

Pre-filled pen

The pre-filled pen has visual and audible signals to confirm the injection was successfully completed. 1

To perform the injection the user should press the green injection button.

  • There will be a loud click that signifies the release of a spring inside the pen. The user should keep holding the clear base firmly against the skin.

  • A second loud click is heard in about 5 to 10 seconds after the first one. It indicates that the injection is complete.

  • Following the injection completion, the grey plunger will now be visible below the device label.1,2

During the delivery, the user might not hear clicks or can hear a soft click before the second loud click. The user should always check the position of the grey plunger at the top of the clear base after the injection. The grey plunger is the most important indicator of a successful dose delivery.1

Pre-filled syringe

The pre-filled syringe has visual signals to confirm the injection was successfully completed.1

To perform the injection the user should slowly push the plunger all the way in until all the medicine is injected. The grey syringe plunger should be pushed all the way to the end of the syringe. The user should gently remove the needle from the skin.

The injection is complete when:

  • the green plunger rod is visible through the body of the syringe

  • the grey syringe plunger is pushed all the way to the end of the syringe2

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Taltz EU Patient Information Leaflet – Instructions for Use, Utrecht, The Netherlands: Eli Lilly Nederland B.V.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: November 13, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question